legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

# Loyola University Chicago Stritch School of Medicine joins Caris Precision Oncology AllianceÔäó (POA)

## Introduction
Loyola University Chicago Stritch School of Medicine has recently become a member of Caris Precision Oncology AllianceÔäó (POA), a network of leading cancer centers and research consortia dedicated to advancing precision medicine and biomarker-driven research. By joining the alliance, Loyola will have access to Caris’ extensive database and AI bioinformatics platform, enabling innovative research to improve clinical outcomes for cancer patients.

## The Caris Precision Oncology Alliance
The Caris Precision Oncology Alliance is a global network of 89 cancer centers, academic institutions, research consortia, and healthcare systems. Its members collaborate to establish and optimize standards of care for molecular testing in oncology, leveraging Caris’ highly sophisticated AI bioinformatics and machine learning capabilities. This alliance aims to improve clinical outcomes for cancer patients through precision oncology and biomarker-driven research.

## Benefits for Loyola University Chicago’s Stritch School of Medicine
By joining the Caris Precision Oncology Alliance, Loyola University Chicago’s Stritch School of Medicine gains access to Caris’ massive clinico-genomic database and AI technology. This enables Loyola’s physicians and researchers to analyze and unravel the molecular complexity of cancer, leading to the development of evidence-based standards for cancer profiling and molecular testing. The alliance also offers early access to biomarker-directed trials sponsored by biopharma, providing additional opportunities for innovative research.

## Collaboration and Vision Alignment
Loyola University Chicago’s Stritch School of Medicine and the Cardinal Bernardin Cancer Center are welcomed into the growing Caris Precision Oncology Alliance network. Chairman of the POA, Chadi Nabhan, expressed excitement about collaborating with Loyola University Chicago and highlighted the shared vision of leveraging big data and precision oncology research to improve outcomes for all cancer patients.

## About Caris Life Sciences
Caris Life Sciences is a leading next-generation AI TechBio company and precision medicine pioneer. By combining molecular science and AI, Caris aims to revolutionize healthcare and improve patient outcomes. The company has developed a large-scale, clinico-genomic database and advanced artificial intelligence algorithms to analyze and understand the molecular complexity of diseases. Caris offers comprehensive molecular profiling and precise medicine tools for early detection, diagnosis, therapy selection, and drug development.

## About Loyola University Chicago
Founded in 1870, Loyola University Chicago is one of the largest Jesuit, Catholic universities in the United States. With multiple campuses and schools, Loyola is known for its community service and engagement. Loyola University Chicago’s Stritch School of Medicine is among the prestigious institutions joining the Caris Precision Oncology Alliance network.

## Media Contacts
For further information or inquiries, please reach out to the following contacts:

– Caris Life Sciences: Lisa Burgner, [email┬áprotected], 214.294.5606
– Loyola University Chicago:
– Matt McDermott, [email┬áprotected]
– Naomi Gitlin, [email┬áprotected]
– Loyola Medicine (Trinity Health): Carol Eggers, [email┬áprotected]

[Source: Caris Life Sciences](https://www.carislifesciences.com/)

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link